-
1Academic Journal
المؤلفون: Yu. A. Dolgikh, S. V. Bulgakova, L. A. Sharonova, O. V. Kosareva, E. V. Treneva, P. Ya. Merzlova, D. Р. Kurmayev, Ю. А. Долгих, С. В. Булгакова, Л. А. Шаронова, О. В. Косарева, Е. В. Тренева, П. Я. Мерзлова, Д. П. Курмаев
المصدر: Meditsinskiy sovet = Medical Council; № 13 (2024); 156-163 ; Медицинский Совет; № 13 (2024); 156-163 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: L-тироксин, isolated hypothyroxinemia, pregnancy, psycho-physical development of the child, L-thyroxine, изолированная гипотироксинемия, беременность, психофизическое развитие ребенка
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8514/7485; Gaberšček S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol. 2011;7(5):697-706. https://doi.org/10.1586/eci.11.42.; Moleti M, Trimarchi F, Vermiglio А. Thyroid physiology in pregnancy. Endocr Pract. 2014;20(6):589-596. https://doi.org/10.4158/EP13341.RA.; Baba KA, Azar ST. Thyroid dysfunction in pregnancy. Int J Gen Med. 2012;5:227-230. https://doi.org/10.2147/IJGM.S27009.; Marqusee E, Braverman LE, Lawrence JE, Carroll JS, Seely EW. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin Endocrinol Metab. 2000;85(11):4407-4410. https://doi.org/10.1210/jcem.85.11.6975.; Krassas G, Karras SN, Pontikides N. Thyroid diseases during pregnancy: a number of important issues. Hormones (Athens). 2015;14(1):59-69. https://doi.org/10.1007/BF03401381.; Maciel LM, Magalhaes PK. Thyroid and pregnancy. Arq Bras Endocrinol Metabol. 2008;52(7):1084-1095. https://doi.org/10.1590/s0004-27302008000700004.; Loubiere LS, Vasilopoulou E, Bulmer JN, Taylor PM, Stieger B, Verrey F et al. Expression of thyroid hormone transporters in the human placenta and changes associated with intrauterine growth restriction. Placenta. 2010;31(4):295-304. https://doi.org/10.1016/j.placenta.2010.01.013.; de Escobar GM, Obregon MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab. 2004;18(2):225-248. https://doi.org/10.1016/j.beem.2004.03.012.; Williams GR. Neurodevelopmental and neurophysiological actions of thyroid hormone. J Neuroendocrinol. 2008;20(6):784-794. https://doi.org/10.1111/j.1365-2826.2008.01733.x.; Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. https://doi.org/10.1089/thy.2016.0457.; Lazarus JH. Screening for thyroid dysfunction in pregnancy: is it worthwhile? J Thyroid Res. 2011;2011:397012. https://doi.org/10.4061/2011/397012.; Teng W, Shan Z, Patil-Sisodia K, Cooper DS. Hypothyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):228-237. https://doi.org/10.1016/S2213-8587(13)70109-8.; Dieguez M, Herrero A, Avello N. Suarez P. Delgado E, Menendez E. Prevalence of thyroid dysfunction in women in early pregnancy: does it increase with maternal age? Clin Endocrinol (Oxf). 2016;84(1):121-126. https://doi.org/10.1111/cen.12693.; Yazbeck CF, Sullivan SD. Thyroid disorders during pregnancy. Med Clin North Am. 2012;96(2):235-256. https://doi.org/10.1016/j.mcna.2012.01.004.; Negro R, Mestman JH. Thyroid disease in pregnancy. Best Pract Res Clin Endocrinol Metab. 2011;25(6):927-943. https://doi.org/10.1016/j.beem.2011.07.010.; Brenta G, Vaisman M, Sgarbi JA, Bergoglio LM, Andrada NC, Bravo PP et al. Task Force on Hypothyroidism of the Latin American Thyroid Society (LATS). Clinical practice guidelines for the management of hypothyroidism. Arq Bras Endocrinol Metabol. 2013;57(4):265-291. https://doi.org/10.1590/s0004-27302013000400003.; Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. Eur Thyroid J. 2014;3(2):76-94. https://doi.org/10.1159/000362597.; Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone M et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab. 1991;73(2):421-427. https://doi.org/10.1210/jcem-73-2-421.; Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid. 2002;12(1):63-68. https://doi.org/10.1089/105072502753451986.; Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. Eur J Endocrinol. 2004;151(3):25-37. https://doi.org/10.1530/eje.0.151u025.; Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341(8):549-555. https://doi.org/10.1056/NEJM199908193410801.; Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R et al. American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081-1125. https://doi.org/10.1089/thy.2011.0087.; Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005;105(2):239-245. https://doi.org/10.1097/01.AOG.0000152345.99421.22.; Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol. 2007;109(5):1129-1135. https://doi.org/10.1097/01.AOG.0000262054.03531.24.; Su PY, Huang K, Hao JH, Xu YQ, Yan SQ, Li T et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab. 2011;96(10):3234-3241. https://doi.org/10.1210/jc.2011-0274.; Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Alavi Majd H, Azizi F. Effects of levothyroxine treatment on pregnancy outcomes in pregnant women with autoimmune thyroid disease. Eur J Endocrinol. 2017;176(2):253-265. https://doi.org/10.1530/EJE-16-0548.; Leon G, Murcia M, Rebagliato M, Alvarez-Pedrerol M, Castilla AM, Basterrechea M et al. Maternal thyroid dysfunction during gestation, preterm delivery, and birthweight. The Infancia y Medio Ambiente Cohort, Spain. Paediatr Perinat Epidemiol. 2015;29(2):113-22. https://doi.org/10.1111/ppe.12172.; Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. Clin Endocrinol (Oxf). 2003;59(3):282-288. https://doi.org/10.1046/j.1365-2265.2003.01822.x.; Pop VJ, Brouwers EP, Wijnen H, Oei G, Essed GG, Vader HL. Low concentrations of maternal thyroxin during early gestation: a risk factor of breech presentation? BJOG. 2004;111(9):925-90. https://doi.org/10.1111/j.1471-0528.2004.00213.x.; Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, Spratt DI et al. Mid-gestational maternal free thyroxine concentration and offspring neurocognitive development at age two years. J Clin Endocrinol Metab. 2012;97(1):22-28. https://doi.org/10.1210/jc.2011-1772.; Korevaar TI. Evidence-Based Tightrope Walking: The 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):309-311. https://doi.org/10.1089/thy.2017.2904O.tko.; Yassa L, Marqusee E, Fawcett R, Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010;95(7):3234-3241. https//doi.org/10.1210/jc.2010-0013.; Yan YQ, Dong ZL, Dong L, Wang FR, Yang XM, Jin XY et al. Trimester- and method-specific reference intervals for thyroid tests in pregnant Chinese women: methodology, euthyroid definition and iodine status can influence the setting of reference intervals. Clin Endocrinol (Oxf). 2011;74(2):262-269. https//doi.org/10.1111/j.1365-2265.2010.03910.x.; Marwaha RK, Chopra S, Gopalakrishnan S, Sharma B, Kanwar RS, Sastry A et al. Establishment of reference range for thyroid hormones in normal pregnant Indian women. BJOG. 2008;115(5):602-606. https://doi.org/10.1111/j.1471-0528.2008.01673.x.; Korevaar TI, Schalekamp-Timmermans S, de Rijke YB, Visser WE, Visser W, de Muinck Keizer-Schrama SM et al. Hypothyroxinemia and TPO-antibody positivity are risk factors for premature delivery: the generation R study. J Clin Endocrinol Metab. 2013;98(11):4382-4390. https//doi.org/10.1210/jc.2013-2855.; Moon HW, Chung HJ, Park CM, Hur M, Yun YM. Establishment of trimester-specific reference intervals for thyroid hormones in Korean pregnant women. Ann Lab Med. 2015;35(2):198-204. https//doi.org/10.3343/alm.2015.35.2.198.; Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W et al. Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? J Clin Endocrinol Metab. 2014;99(1):73-79. https//doi.org/10.1210/jc.2013-1674.; Casey BM, Thom EA, Peaceman AM, Varner MW, Sorokin Y, Hirtz DG et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med. 2017;376(9):815-825. https://doi.org/10.1056/NEJMoa1606205.; Рыбакова АА, Платонова НМ, Никанкина ЛВ, Малышева НМ, Елфимова АР, Трошина ЕА. Референсные интервалы тиреотропного гормона у беременных женщин, проживающих в центральных регионах РФ. Проблемы эндокринологии. 2022;68(6):43-48. https://doi.org/10.14341/probl13151.; Фадеев ВВ, Моргунова ТБ, Мельниченко ГА, Дедов ИИ. Проект клинических рекомендаций по гипотиреозу. Клиническая и экспериментальная тиреоидология. 2021;17(1):4-13. https://doi.org/10.14341/ket12702.; Schroeder AC, Privalsky ML. Thyroid hormones, t3 and t4, in the brain. Front Endocrinol (Lausanne). 2014;5:40. https://doi.org/10.3389/fendo.2014.00040.; Bernal J, Guadano-Ferraz A, Morte B. Thyroid hormone transporters - functions and clinical implications. Nat Rev Endocrinol. 2015;11(7):406-417. https://doi.org/10.1038/nrendo.2015.66.; Carosa E, Lenzi A, Jannini EA. Thyroid hormone receptors and ligands, tissue distribution and sexual behavior. Mol Cell Endocrinol. 2018;467:49-59. https://doi.org/10.1016/j.mce.2017.11.006.; Абдулхабирова ФМ, Безлепкина ОБ, Бровин ДН, Вадина ТА, Мельниченко ГА, Нагаева ЕВ и др. Клинические рекомендации «Заболевания и состояния, связанные с дефицитом йода». Проблемы эндокринологии. 2021;67(3):10-25. https://doi.org/10.14341/probl12750.; Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351(3):241-249. https://doi.org/10.1056/NEJMoa040079.; Fan X, Wu L. The impact of thyroid abnormalities during pregnancy on subsequent neuropsychological development of the offspring: a meta-analysis. J Matern Fetal Neonatal Med. 2016;29(24):3971-3976. https://doi.org/10.3109/14767058.2016.1152248.; Yang J, Liu Y, Liu H, Zheng H, Li X, Zhu L et al. Associations of maternal iodine status and thyroid function with adverse pregnancy outcomes in Henan Province of China. J Trace Elem Med Biol. 2018;47:104-110. https://doi.org/10.1016/j.jtemb.2018.01.013.; Nassie DI, Ashwal E, Raban O, Ben-Haroush A, Wiznitzer A, Yogev Y et al. Is there an association between subclinical hypothyroidism and preterm uterine contractions? A prospective observational study. J Matern Fetal Neonatal Med. 2017;30(8):881-885. https://doi.org/10.1080/14767058.2016.1191065.; Arbib N, Hadar E, Sneh-Arbib O, Chen R, Wiznitzer A, Gabbay-Benziv R. First trimester thyroid stimulating hormone as an independent risk factor for adverse pregnancy outcome. J Matern Fetal Neonatal Med. 2017;30(18):2174-2178. https://doi.org/10.1080/14767058.2016.1242123.; Korevaar TIM, Steegers EAP, Chaker L, Medici M, Jaddoe VWV, Visser TJ et al. Thyroid function and premature delivery in TPO antibody-negative women: the added value of hCG. J Clin Endocrinol Metab. 2017;102(9): 3360-3367. https://doi.org/10.1210/jc.2017-00846.; Zhao L, Jiang G, Tian X, Zhang X, Zhu T, Chen B et al. Initiation timing effect of levothyroxine treatment on subclinical hypothyroidism in pregnancy. Gynecol Endocrinol. 2018;34(10):845-848. https://doi.org/10.1080/09513590.2018.1451836.; Nazarpour S, Ramezani Tehrani F, Simbar M, Tohidi M, Minooee S, Rahmati M et al. Effects of levothyroxine on pregnant women with subclinical hypothyroidism, negative for thyroid peroxidase antibodies. J Clin Endocrinol Metab. 2018;103(3):926-935. https://doi.org/10.1210/jc.2017-01850.; Maraka S, Mwangi R, McCoy RG, Yao X, Sangaralingham LR, Singh Ospina NM et al. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment. BMJ. 2017;356:i6865. https://doi.org/10.1136/bmj.i6865.; Galofre JC, Haber RS, Mitchell AA, Pessah R, Davies TF. Increased postpartum thyroxine replacement in Hashimoto's thyroiditis. Thyroid. 2010;20(8):901-908. https://doi.org/10.1089/thy.2009.0391.; Thangaratinam S, Tan A, Knox E, Kilby MD, Franklyn J, Coomarasamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ. 2011;342:d2616. https://doi.org/10.1136/bmj.d2616.; Busnelli A, Paffoni A, Fedele L, Somigliana E. The impact of thyroid autoimmunity on IVF/ICSI outcome: a systematic review and meta-analysis. Hum Reprod Update. 2016;22(6):793-794. https://doi.org/10.1093/humupd/dmw034.; Wang H, Gao H, Chi H, Zeng L, Xiao W, Wang Y et al. Effect of levothyroxine on miscarriage among women with normal thyroid function and thyroid autoimmunity undergoing in vitro fertilization and embryo transfer: a randomized clinical trial. JAMA. 2017;318(22):2190-2198. https://doi.org/10.1001/jama.2017.18249.; Rao M, Zeng Z, Zhao S, Tang L. Effect of levothyroxine supplementation on pregnancy outcomes in women with subclinical hypothyroidism and thyroid autoimmuneity undergoing in vitro fertilization/intracytoplasmic sperm injection: an updated meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2018;16(1):92. https://doi.org/10.1186/s12958-018-0410-6.; Asik M, Gunes F, Binnetoglu E, Eroglu M, Bozkurt N, Sen H et al. Decrease in TSH levels after lactose restriction in Hashimoto's thyroiditis patients with lactose intolerance. Endocrine. 2014;46(2):279-284. https://doi.org/10.1007/s12020-013-0065-1.; https://www.med-sovet.pro/jour/article/view/8514
-
2Academic Journal
المؤلفون: S. V. Bulgakova, Yu. A. Dolgikh, L. A. Sharonova, O. V. Kosareva, E. V. Treneva, P. Ya. Merzlova, D. P. Kurmayev, С. В. Булгакова, Ю. А. Долгих, Л. А. Шаронова, О. В. Косарева, Е. В. Тренева, П. Я. Мерзлова, Д. П. Курмаев
المصدر: Meditsinskiy sovet = Medical Council; № 16 (2024); 184-192 ; Медицинский Совет; № 16 (2024); 184-192 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: эссенциальные фосфолипиды, steatohepatitis, metformin, pioglitazone, glucagon-like peptide-1 agonists, essential phospholipids, стеатогепатит, метформин, пиоглитазон, агонисты глюкагоноподобного пептида-1
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8626/7575; Wong VW, Ekstedt M, Wong GL, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842–852. https://doi.org/10.1016/j.jhep.2023.04.036.; Маев ИВ, Андреев ДН, Кучерявый ЮА. Распространенность неалкогольной жировой болезни печени в России: метаанализ. Consilium Medicum. 2023;25(5):313–319. https://doi.org/10.26442/20751753.2023.5.202155.; Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002.; Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347. https://doi.org/10.1097/HEP.0000000000000004.; Евстифеева СЕ, Шальнова СА, Куценко ВА, Яровая ЕБ, Баланова ЮА, Имаева АЭ и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. https://doi.org/10.15829/1728-8800-2022-3356.; Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–e185. https://doi.org/10.1161/atv.0000000000000153.; Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab. 2022;24(2 Suppl.):28–43. https://doi.org/10.1111/dom.14484.; Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. https://doi.org/10.1016/S0140-6736(20)32511-3.; Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018;155(6):1828–1837.e2. https://doi.org/10.1053/j.gastro.2018.08.024.; Thomas JA, Kendall BJ, El-Serag HB, Thrift AP, Macdonald GA. Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2024;9(2):159–169. https://doi.org/10.1016/S2468-1253(23)00275-3.; Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016;65(8):1096–1108. https://doi.org/10.1016/j.metabol.2016.01.001.; Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. https://doi.org/10.1038/nrgastro.2016.147.; Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612. https://doi.org/10.1038/s41575-021-00448-y.; En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–2148. https://doi.org/10.1136/gutjnl-2023-330110.; Буеверов АО, Рощина КМ, Богомолов ПО. Неалкогольная жировая болезнь печени: новый взгляд на аспекты коморбидности. Эффективная фармакотерапия. 2022;18(6):32–38. Режим доступа: https://umedp.ru/articles/nealkogolnaya_zhirovaya_bolezn_pecheni_novyy_vzglyad_na_aspekty_komorbidnosti.html.; Chen X, Xiao J, Pang J, Chen S, Wang Q, Ling W. Pancreatic beta-cell dysfunction is associated with nonalcoholic fatty liver disease. Nutrients. 2021;13(9):3139. https://doi.org/10.3390/nu13093139.; Mitsuhashi K, Hashimoto Y, Hamaguchi M, Obora A, Kojima T et al. Impact of fatty liver disease and metabolic syndrome on incident type 2 diabetes; a population based cohort study. Endocr J. 2017;64(11):1105–1114. https://doi.org/10.1507/endocrj.ej17-0245.; Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg Nutr. 2020;9(2):239–241. https://doi.org/10.21037/hbsn.2019.10.21.; Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11(6):430–445. https://doi.org/10.1111/j.1467-789x.2009.00657.x.; Петунина НА, Тельнова МЭ. Неалкогольная жировая болезнь печени при сахарном диабете 2-го типа. Медицинский совет. 2016;(4):92–95. https://doi.org/10.21518/2079-701X-2016-4-84-89.; Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384:e076388. https://doi.org/10.1136/bmj-2023-076388.; Sinha A, Rajan M, Hoerger T, Pogach L. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010;33(4):695–700. https://doi.org/10.2337/dc09-1488.; Montazeri Z, Hashemi-Madani N, Iraji H, Sohrabi M, Alaei-Shahmiri F, Emami Z et al. Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes. BMC Endocr Disord. 2023;23(1):202. https://doi.org/10.1186/s12902-023-01460-w.; Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17(4):e1003100. https://doi.org/10.1371/journal.pmed.1003100.; Вian H, Zhu X, Xia M, Yan H, Chang X, Hu X et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26(4):444–453. https://doi.org/10.4158/EP-2019-0342.; Павлов ЧС, Глушенков ДВ, Коновалова ОН, Ивашкин ВТ. Сфера клинического применения неинвазивных методов оценки фиброза печени: результаты собственных исследований в многопрофильном стационаре. Клиническая медицина. 2009;87(11):40–45. Режим доступа: https://elibrary.ru/lajkvx.; Голованова ЕВ, Туркина СВ, Райхельсон КЛ, Оковитый СВ, Драпкина ОМ, Маев ИВ и др. Неалкогольная жировая болезнь печени у взрослых: клинические рекомендации. М.; 2022. 65 с. Режим доступа: http://disuria.ru/_ld/12/1229_kr22K76p0K74p6M.pdf.; Лазебник ЛБ, Радченко ВГ, Голованова ЕВ, Звенигородская ЛА, Конев ЮВ, Селиверстов ПВ и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия). Терапия. 2017;(3):6–23. Режим доступа: https://elibrary.ru/yqzfez.; Лазебник ЛБ, Голованова ЕВ, Туркина СВ, Райхельсон КЛ, Оковитый СВ, Драпкина ОМ и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4–52. https://doi.org/10.31146/1682-8658-ecg-185-1-4-52.; Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–3373. https://doi.org/10.3748/wjg.v24.i30.3361.; Алдашева ЖА. Неалкогольная жировая болезнь печени: роль ультразвукового метода исследования в ее диагностике. Вестник КРСУ. 2013;13(11):28–31. Режим доступа: https://elibrary.ru/sngugv.; Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122. https://doi.org/10.1055/s-0034-1375953.; Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367.; EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004.; Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004;39(3):608–616. https://doi.org/10.1002/hep.20093.; Watanabe M, Tozzi R, Risi R, Tuccinardi D, Mariani S, Basciani S et al. et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature. Obes Rev. 2020;21(8):e13024. https://doi.org/10.1111/obr.13024.; Mirabelli M, Chiefari E, Arcidiacono B, Corigliano DM, Brunetti FS, Maggisano V et al. Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Nutrients. 2020;12:1066. https://doi.org/10.3390/nu12041066.; Van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr. 2018;18(2):89–101. https://doi.org/10.3727/105221617X15124844266408.; Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol. 2017;66(1):142–152. https://doi.org/10.1016/j.jhep.2016.08.023.; Oh YS, Kim HJ, Ryu SJ, Cho KA, Park YS, Park H et al. Exercise type and muscle fiber specific induction of caveolin-1 expression for insulin sensitivity of skeletal muscle. Exp Mol Med. 2007;39(3):395–401. https://doi.org/10.1038/emm.2007.44.; Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87(2):569–574. https://doi.org/10.1210/jcem.87.2.8261.; Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod. 2001;16(8):1625–1631. https://doi.org/10.1093/humrep/16.8.1625; Sin HY, Kim JY, Jung KH. Total cholesterol, high density lipoprotein and triglyceride for cardiovascular disease in elderly patients treated with metformin. Arch Pharm Res. 2011;34(1):99–107. https://doi.org/10.1007/s12272-011-0112-5.; Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48(1):78–87. https://doi.org/10.3109/00365521.2012.719926.; Мисникова ИВ, Древаль АВ, Лакеева ТС. Влияние метформина и пиоглитазона на факторы риска развития сердечно-сосудистой патологии у пациентов с сахарным диабетом 2-го типа, установленным во время скрининга. Альманах клинической медицины. 2013;(29):23–28. Режим доступа: https://almclinmed.ru/jour/article/view/26.; Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–2307. https://doi.org/10.1056/NEJMoa060326.; Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–690. https://doi.org/10.1016/S0140-6736(15)00803-X.; Грищенко ЕБ. Место фосфолипидных препаратов в современной терапевтической практике. Медицинский совет. 2013;(3):52–57. https://doi.org/10.21518/2079-701X-2013-3-52-57.; Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AI. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol. 2015;16(3–4):99–104. https://doi.org/10.1016/j.ajg.2015.09.001.; Sas Е, Grinevich V, Efimov O, Shcherbina N. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J Hepatol. 2013;58(Suppl 1):S549. https://doi.org/10.1016/S0168-8278(13)61365-3; Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7(1):e000341. https://doi.org/10.1136/bmjgast-2019-000341.; Maev I, Pavlov Ch, Starostin KM, Popovic B. Практические данные о положительных эффектах эссенциальных фосфолипидов у пациентов с неалкогольной жировой болезнью печени. Evidence for Self-Medication. 2022;2. https://doi.org/10.52778/efsm.22.0104; Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368. https://doi.org/10.1136/bmjgast-2019-000368.; Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019;6(1):e000307. https://doi.org/10.1136/bmjgast-2019-000307.; Ivashkin VT, Maevskaya MV, Shirokova EN, Maev IV, Samsonov AA, Sas EI et al. Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies. Drugs Real World Outcomes. 2021;8(3):369–382. https://doi.org/10.1007/s40801-021-00250-x.; Küllenberg D, Taylor LA, Schneider M, Massing U. Health effects of dietary phospholipids. Lipids Health Dis. 2012;11:3. https://doi.org/10.1186/1476-511X-11-3.; Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis. World J Clin Cases. 2020;8(21):5235–5249. https://doi.org/10.12998/wjcc.v8.i21.5235.
-
3Academic Journal
المؤلفون: S. V. Bulgakova, P. Ya. Merzlova, O. A. Novikova, L. А. Sharonova, Yu. A. Dolgikh, O. V. Kosareva, С. В. Булгакова, П. Я. Мерзлова, О. А. Новикова, Л. А. Шаронова, Ю. А. Долгих, О. В. Косарева
المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 226-233 ; Медицинский Совет; № 6 (2024); 226-233 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: хронический аутоиммунный тиреоидит, polyglandular insufficiency syndrome, Schmidt syndrome, adrenal insufficiency, autoimmune thyroid diseases, синдром полигландулярной недостаточности, синдром Шмидта, хроническая надпочечниковая недостаточность
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8292/7315; Воробьев СВ, Хрипун ИА, Кузьменко НА, Стрельцова ЕМ, Петровская ЕЮ. Синдром Шмидта в клинической практике. Южно-Российский журнал терапевтической практики. 2020;1(2):88–92. https://doi.org/10.21886/2712-8156-2020-1-2-88-92.; Bain A, Stewart M, Mwamure P, Nirmalaraj K. Addison’s disease in a patient with hypothyroidism: autoimmune polyglandular syndrome type 2. BMJ Case Rep. 2015:bcr2015210506. https://doi.org/10.1136/bcr-2015-210506.; Давыдчик ЭВ, Снежицкий ВА, Никонова ЛВ, Тишковский С.В. Эндокринные аспекты эндокринных полигландулярных синдромов. Журнал Гродненского государственного медицинского университета. 2016;(2):15–21. Режим доступа: http://journal-grsmu.by/index.php/ojs/article/view/1929.; Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. 2003;74(1):9–33. Available at: https://pubmed.ncbi.nlm.nih.gov/12817789/.; Трошина ЕА, Ларина АА, Терехова МА. Аутоиммунный полигландулярный синдром взрослых: молекулярно-генетические и клинические характеристики (лекция). Consilium Medicum. 2019;21(4):91–96. Режим доступа: https://consilium.orscience.ru/2075-1753/article/view/96861.; Ларина АА, Шаповальянц ОС, Мазурина НВ, Трошина ЕА. Диагностика и лечение аутоиммунного полигландулярного синдрома у взрослых. Клиническая медицина. 2012;90(8):64–66. Режим доступа: https://www.elibrary.ru/rbfzrt.; Singh G, Jialal I. Polyglandular Autoimmune Syndrome Type II. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK525992/.; Дедов ИИ, Мельниченко ГА (ред.). Эндокринология: национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2022. 1112 с.; Газизова ГР, Шайдуллина МР, Валеева ФВ, Галиева АИ. Аутоиммунный полигландулярный синдром 3 типа. Медицинский вестник Юга России. 2020;11(4):78–83. https://doi.org/10.21886/2219-8075-2020-11-4-78-83.; Kahaly GJ, Frommer L, Schuppan D. Celiac Disease and Glandular Autoimmunity. Nutrients. 2018;10(7):814. https://doi.org/10.3390/nu10070814.; Мокрышева НГ, Мельниченко ГА, Трошина ЕА, Юкина МЮ, Фадеев ВВ, Бельцевич ДГ и др. Первичная надпочечниковая недостаточность: клинические рекомендации. М.; 2021. 72 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/524_2.; Meyer G, Badenhoop K, Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2·5-fold risk for adrenal crises: German Health insurance data 2010–2013. Clin Endocrinol (Oxf). 2016;85(3):347–353. https://doi.org/10.1111/cen.13043.; Ларина АА, Трошина ЕА, Иванова ОН. Аутоиммунные полигландулярные синдромы взрослых: генетические и иммунологические критерии диагностики. Проблемы эндокринологии. 2014;60(3):43–52. https://doi.org/10.14341/probl201460343-52.; Дедов ИИ, Шестакова МВ, Майоров АЮ, Шамхалова МШ, Никонова ТВ, Сухарева ОЮ и др. Сахарный диабет 1-го типа у взрослых. Сахарный диабет. 2020;23(1S):42–114. https://doi.org/10.14341/DM12505.; Дедов ИИ, Мельниченко ГА, Фадеев ВВ, Моргунова ТБ. Гипотиреоз: клинические рекомендации. М.; 2021. 34. Режим доступа: https://cr.minzdrav.gov.ru/recomend/531_3.; https://www.med-sovet.pro/jour/article/view/8292